Pieris stock: buy or sell?

PIRS stock price: $4.54 -5.61% At close on August 22nd, 2019

Updated on:
August 22nd, 2019


Shares of Pieris Pharmaceuticals collapsed a frightening -5.61% and closed at $4.54.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Should I buy Pieris stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Pieris stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Pieris stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we collected 5 ratings published for PIRS stock in the last 30 days.

The general sentiment of these ratings is bullish for PIRS stock, with 4 positive ratings.
Is PIRS a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-16William Blairn/aBuy
2019-8-1HC Wainwrightn/aBuy
2019-7-30Robert W. BairdOutperformNeutral
2019-6-17HC Wainwrightn/aBuy
2019-3-19HC Wainwrightn/aBuy

Pieris stock analysis

Daily outlook

Pieris shares collapsed -5.61% to $4.54 yesterday.

Pieris shares collapsed -5.61% to $4.54 yesterday. On Jul 12th, SMA100d and SMA200d crossed up triggering a rise of 2.71%. Since May when PIRS stock price broke up the SMA200d line, it gained $0.79 (21.07%).

PIRS stock chart (daily)

Weekly outlook

Pieris Pharmaceuticals closed this week at $4.54 and plummed a frightening -9.20%. Late July PIRS skyrocketed an extraordinary 14.41% in just one week. For 3 weeks in a row, price slid and lost a -21.26%.

Pieris stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since SMA20w and SMA40w crossed up early July, PIRS price slid a -3.40%. Since price and SMA40w lines crossed up late May, PIRS climbed $0.95 (26.46%).

PIRS stock chart (weekly)

Pieris stock price history

Pieris stock went public on January 2nd, 2015 with a price of $2.751. Since then, PIRS stock surged a 65.10%, with an average of 16.30% per year. If you had invested right after PIRS's IPO a $1,000 in Pieris stock in 2015, it would worth $651.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Pieris stock historical price chart

PIRS stock reached 52-week highs on July/29 at $6.04, and all-time highs 2018-02-13 with a price of 9.75.

Pieris stock price target is $6.30

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' PIRS stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 3 price predictions for PIRS stock:
PIRS stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-1HC WainwrightReiteratesn/a$7.00-
2019-7-30Robert W. BairdDowngradesn/a$5.00-
2019-6-17HC WainwrightSet Price Targetn/a$7.00-
(in average)$0.00$6.300.0%
The price target for Pieris Pharmaceuticals stock is $6.30, moving in a range between $7.00 and $5.00. In average, analysts' outlook on PIRS price target is stable from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, Pieris Pharmaceuticals reported its latest financial data, posting a dazzling growth for the Earnings per Share (EPS). Analyst expected $-0.16 per share, but Pieris Pharmaceuticals posted $-0.21.
PIRS earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual turnover report draw a dazzling gain of 15.14% to $29.10 million USD. When comparing 2018 vs 2017, in contrary, profit margin (that is, the net income divided by revenues) plunged a -22.12% to -91.93%.

PIRS annual Sales and Income evolution
2013$12 M-$0.07 M0.5%-
2014$1,772 M14,153.74%$108 M6.1%162,341.84%
2014$5.37 M-99.70%$-9.85 M-183.6%-109.16%
2015$1,885 M35,026.61%$75 M4.0%-863.05%
2015$2.93 M-99.84%$-14.06 M-479.5%-118.70%
2016$1,892 M64,438.72%$40 M2.1%-381.89%
2016$5.83 M-99.69%$-22.80 M-391.0%-157.53%
2017$1,828 M31,259.17%$30 M1.6%-232.15%
2017$25 M-98.62%$-17.65 M-69.8%-158.57%
2018$29 M15.14%$-26.75 M-91.9%51.61%

Quarterly financial results

Pieris posted $4.91 million in revenues for 2018-Q4, a -41.11% less compared to previous quarter. Reported quarter earnings marked $-11.68 M with a profit margin of -237.73%. Profit margin plunged a -164.00% compared to previous quarter when profit margin was -73.73%. When comparing sales to same quarter last year, Pieris Pharmaceuticals sales marked a bloodcurdling decrease and plummed a -72.93%. Looking back to recent quarterly results, Pieris Pharmaceuticals posted 2 negative quarters in a row.
PIRS quarterly Sales and Income evolution
2017-Q1$1 M-$-7.99 M-596.3%-
2017-Q2$2 M38.06%$-10.08 M-544.9%26.16%
2017-Q3$4 M112.28%$-7.06 M-179.7%-29.97%
2017-Q4$18 M362.21%$7.49 M41.3%-206.12%
2018-Q1$4 M-77.13%$-8.71 M-209.9%-216.33%
2018-Q2$12 M181.58%$-0.20 M-1.7%-97.67%
2018-Q3$8 M-28.62%$-6.15 M-73.7%2,931.03%
2018-Q4$5 M-41.11%$-11.68 M-237.7%89.86%

Pieris ownership

When you are planning to invest in shares of a company, it's worth to review its ownership structure.

Pieris Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.23% of all shares.

In case of Pieris Pharmaceuticals stock, 72.84% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for PIRS stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Pieris:

Market cap$223.6 M$0.0 M$151.1 M$305.3 M$64.8 M
Total shares49.3 M0.0 M39.2 M95.7 M11.0 M
Float shares45.0 M68.0 M46.3 M35.3 M5.6 M
  - Institutional holdings (%)72.8%0.0%67.9%21.0%53.7%
  - Insider holdings (%)0.2%0.0%1.3%41.4%20.9%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Pieris summary

Thursday, August 22nd, 2019
Day range$4.50 - $4.78
Previous close$4.81
Session gain-5.61%
Average true range$0.33
50d mov avg$4.73
100d mov avg$4.15
200d mov avg$3.62
Daily pattern
Weekly pattern lt06a

Pieris performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked Aurinia Pharmaceuticals, Calithera Biosciences, CASI Pharmaceuticals and Champions Oncology as the bechmarking frame for Pieris stock.
PIRSPieris Pharmaceut...2.95%47.40%-13.69%
AUPHAurinia Pharmaceu...-13.06%-5.33%8.32%
CALACalithera Bioscie...-32.81%-32.10%-18.95%
CASICASI Pharmaceutic...0.95%-12.12%-56.54%
CSBRChampions Oncolog...-40.30%-33.22%-31.99%

Pieris competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for Pieris Pharmaceuticals. We chose 4 companies as Pieris Pharmaceuticals competitors as they are in the same industry or have similar market objectives.